Pricing Log in Create free account

Clene Inc. (CLNN) vs INmune Bio, Inc. (INMB)

Clene Inc. and INmune Bio, Inc. are both Biotechnology companies. Clene Inc. and INmune Bio, Inc. are of similar size ($47.0M and $45.8M). Clene Inc. grew revenue faster over the last twelve months: −31.1% against −51.6%. INmune Bio, Inc. has the higher net margin (0.00% vs −20,059.9%) and the lower return on invested capital (−646.9% vs 0.00%). Across the 17 metrics below, INmune Bio, Inc. leads on 10 and Clene Inc. on 7.

Valuation

Metric CLNN INMB Biotechnology median
P/E n/m n/m 8.50
P/S 194.86 310.73 9.71
P/B n/m 2.06 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 238.72 210.43 9.21
Earnings yield (112.90%) (42.68%) (33.15%)
Free cash flow yield (41.54%) (39.17%) (25.50%)

Profitability

Metric CLNN INMB Biotechnology median
Gross margin 70.05% 100.00% 65.16%
Operating margin (10,431.98%) 0.00% 0.00%
Net margin (20,059.90%) 0.00% 0.00%
Free cash flow margin (8,095.43%) 0.00% 0.00%
Return on equity 237.15% (74.82%) (56.36%)
Return on assets (174.99%) (57.08%) (48.04%)
Return on invested capital 0.00% (646.94%) 0.00%

Growth

Metric CLNN INMB Biotechnology median
Revenue growth (TTM) (31.12%) (51.61%) 6.02%
EPS growth (last fiscal year) 53.26% 11.85% 30.26%
Revenue growth, 5-year CAGR (0.59%) 35.37% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLNN INMB Biotechnology median
Debt to equity (0.74) 0.00 0.00
Current ratio 3.07 4.04 4.72
Net debt to EBITDA (0.39) 0.52 0.96

Dividend

Metric CLNN INMB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLNN INMB Biotechnology median
Market cap 46.98m 45.80m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack